

December 8, 2025

HEPATITIS C TREATMENT COVERAGE CHANGES COMING IN JAN. 2026

BACKGROUND

The Texas Drug Utilization Review Board reviewed the Hepatitis C drug class for preferred drug list (PDL) status at its meeting on Oct. 24, 2025. HHSC will implement the Hepatitis C PDL class recommendations on Jan. 1, 2026.

Notable changes are highlighted as follows:

- The following drugs will be moving from “NPD” (non-preferred) to “PDL” (preferred).
 - o EPCLUSA TAB 400-100
 - o EPCLUSA TAB 200-50MG
 - o EPCLUSA PAK 150-37.5MG
- The following drugs will be moving from “NAP” (no auto PA) to “PDL” (preferred).
 - o SOFOSUVIR/VELPATASVIR TAB 400-100

Additional information forthcoming.

QUESTIONS

For any questions regarding this notice, please contact your Community Provider Performance Manager (provider representative). E-mail: ProviderRelationsInquiries@CommunityHealthChoice.org